These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 25673087

  • 1. Pharmacokinetics, pharmacodynamics and food effect of LB30870, a novel direct thrombin inhibitor, after single oral doses in healthy men.
    Kim J, Lee SH, Boyce M, Warrington S, Cho KH, Yoon SK, Park HD, Kim A.
    Xenobiotica; 2015; 45(8):663-71. PubMed ID: 25673087
    [Abstract] [Full Text] [Related]

  • 2. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
    Stangier J, Rathgen K, Stähle H, Gansser D, Roth W.
    Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
    [Abstract] [Full Text] [Related]

  • 3. Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.
    Park HD, Lee SH, Kim TH, Lee SH, Cho KH, Kim A.
    Bioorg Med Chem Lett; 2013 Sep 01; 23(17):4779-84. PubMed ID: 23899618
    [Abstract] [Full Text] [Related]

  • 4. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.
    Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves RA, LaCreta F.
    Br J Clin Pharmacol; 2013 Feb 01; 75(2):476-87. PubMed ID: 22759198
    [Abstract] [Full Text] [Related]

  • 5. Crossover dose escalation study to assess safety, pharmacokinetics, and pharmacodynamics of single doses of R1663, an oral factor Xa inhibitor, in healthy male volunteers.
    Schmitt C, Pannier A, McIntyre C, Zandt H, Ciorciaro C, Winters K, Pepper T.
    J Clin Pharmacol; 2012 Apr 01; 52(4):499-510. PubMed ID: 21566199
    [Abstract] [Full Text] [Related]

  • 6. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
    Stampfuss J, Kubitza D, Becka M, Mueck W.
    Int J Clin Pharmacol Ther; 2013 Jul 01; 51(7):549-61. PubMed ID: 23458226
    [Abstract] [Full Text] [Related]

  • 7. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
    Harder S, Graff J, Klinkhardt U, von Hentig N, Walenga JM, Watanabe H, Osakabe M, Breddin HK.
    Thromb Haemost; 2004 Jun 01; 91(6):1137-45. PubMed ID: 15175800
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men.
    Wernevik LC, Nyström P, Johnsson G, Nakanishi T, Eriksson UG.
    Clin Pharmacokinet; 2006 Jun 01; 45(1):77-84. PubMed ID: 16430312
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
    Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S.
    J Clin Pharmacol; 2010 Jul 01; 50(7):743-53. PubMed ID: 20081065
    [Abstract] [Full Text] [Related]

  • 11. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
    Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, Lang B, Ramael S, Moschetti V, Gruenenfelder F, Reilly P, Kreuzer J.
    Lancet; 2015 Aug 15; 386(9994):680-90. PubMed ID: 26088268
    [Abstract] [Full Text] [Related]

  • 12. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
    Fowler A, Koenen R, Hilbert J, Blatchford J, Kappeler D, Benediktus E, Wood C, Gupta A.
    J Clin Pharmacol; 2017 Nov 15; 57(11):1444-1453. PubMed ID: 28609567
    [Abstract] [Full Text] [Related]

  • 13. Clinical safety, tolerability, pharmacokinetics and pharmacodynamics of the novel factor Xa inhibitor DY-807f in healthy volunteers.
    Ogata K, Shimizu T, Masumoto H, Oguma T, Sugiyama N, Kunitada S.
    Thromb Res; 2015 Apr 15; 135(4):594-601. PubMed ID: 25700621
    [Abstract] [Full Text] [Related]

  • 14. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH, Lee H, Paik SH, Lee JH, Yoo BW, Kim JH, Tan HK, Kim SL.
    Am J Cardiovasc Drugs; 2011 Oct 01; 11(5):335-46. PubMed ID: 21910510
    [Abstract] [Full Text] [Related]

  • 15. Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue.
    van Iersel T, Stroissnig H, Giesen P, Wemer J, Wilhelm-Ogunbiyi K.
    Thromb Haemost; 2011 Feb 01; 105(2):302-12. PubMed ID: 21103657
    [Abstract] [Full Text] [Related]

  • 16. Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.
    Barbier AJ, Hilhorst M, Van Vliet A, Snyder P, Palfreyman MG, Gawryl M, Dgetluck N, Massaro M, Tiessen R, Timmerman W, Hilt DC.
    Clin Ther; 2015 Feb 01; 37(2):311-24. PubMed ID: 25438724
    [Abstract] [Full Text] [Related]

  • 17. Safety, Pharmacokinetics and Pharmacodynamics of TNHH, a Novel Targeted Neutrophil-Inhibitory Hirulog Hybrid Glycoprotein, in Healthy Volunteers.
    Gou ZP, Song ZH, Chen XG, Hu XC, Wang Y, Fan K, Cai YM, Zheng L.
    CNS Drugs; 2019 Jun 01; 33(6):605-614. PubMed ID: 31093952
    [Abstract] [Full Text] [Related]

  • 18. A Food Effect Study of an Oral Thrombin Inhibitor and Prodrug Approach To Mitigate It.
    Lee J, Kim B, Kim TH, Lee SH, Park HD, Chung K, Lee SH, Paek S, Kim EE, Yoon S, Kim A.
    Mol Pharm; 2016 Apr 04; 13(4):1197-205. PubMed ID: 26886576
    [Abstract] [Full Text] [Related]

  • 19. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C, Bujanover S, Kareht S, Rapoport AM.
    Headache; 2015 Feb 04; 55(2):265-75. PubMed ID: 25546369
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of D-ribose pharmacokinetics, dose proportionality, food effect, and pharmacodynamics after oral solution administration in healthy male and female subjects.
    Thompson J, Neutel J, Homer K, Tempero K, Shah A, Khankari R.
    J Clin Pharmacol; 2014 May 04; 54(5):546-54. PubMed ID: 24272966
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.